The association between congestive heart failure and chronic renal disease

被引:156
作者
Silverberg, D
Wexler, D
Blum, M
Schwartz, D
Iaina, A
机构
[1] Tel Aviv Sourasky Med Ctr, Dept Nephrol, IL-64239 Tel Aviv, Israel
[2] Tel Aviv Sourasky Med Ctr, Dept Cardiol, IL-64239 Tel Aviv, Israel
关键词
anemia; erythropoietin; heart failure; progression of renal disease; renal failure;
D O I
10.1097/00041552-200403000-00004
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Recent findings on the relationship between congestive heart failure and renal failure are summarized in this review. Recent findings Congestive heart failure is found in about one-quarter of cases of chronic kidney disease. The most common cause of congestive heart failure is ischemic heart disease. The prevalence of congestive heart failure increases greatly as the patient's renal function deteriorates, and, at end-stage renal disease, can reach 65-70%. There is mounting evidence that chronic kidney disease itself is a major contributor to severe cardiac damage and, conversely, that congestive heart failure is a major cause of progressive chronic kidney disease. Uncontrolled congestive heart failure is often associated with a rapid fall in renal function and adequate control of congestive heart failure can prevent this. The opposite is also true: treatment of chronic kidney disease can prevent congestive heart failure. There is new evidence showing the cardioprotective effect of carvedilol in patients on dialysis, and of simvastatin and eplerenone in patients with congestive heart failure. Use of non-steroidal anti-inflammatory drugs doubles the rate of hospitalization in patients with congestive heart failure. Anemia has been found in one-third to half the cases of congestive heart failure, and may be caused not only by chronic kidney disease but by the congestive heart failure itself. The anemia is associated with worsening cardiac and renal status and often with signs of malnutrition. Control of the anemia and aggressive use of the recommended medication for congestive heart failure may improve the cardiac function, patient function and exercise capacity, stabilize the renal function, reduce hospitalization and improve quality of life. Congestive heart failure, chronic kidney disease and anemia therefore appear to act together in a vicious circle in which each condition causes or exacerbates the other. Both congestive heart failure and anemia are often undertreated. Cooperation between nephrologists and other physicians in the treatment of patients with anemic congestive heart failure may improve the quality of care and the subsequent prognosis for both congestive heart failure and chronic kidney disease. Summary Adequate and early detection and aggressive treatment of congestive heart failure and chronic kidney disease and the associated anemia may markedly slow the progression of both diseases.
引用
收藏
页码:163 / 170
页数:8
相关论文
共 71 条
[1]   Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction [J].
Al-Ahmad, A ;
Rand, WM ;
Manjunath, G ;
Konstam, MA ;
Salem, DN ;
Levey, AS ;
Sarnak, MJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (04) :955-962
[2]   Why is coronary heart disease of uraemic patients so frequent and so devastating? [J].
Amann, K ;
Ritz, C ;
Adamczak, M ;
Ritz, E .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (04) :631-640
[3]  
BATER DC, 2002, SEMIN ARTHRITIS RHEU, V32, P33
[4]   Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy [J].
Berl, T ;
Hunsicker, LG ;
Lewis, JB ;
Pfeffer, MA ;
Porush, JG ;
Rouleau, JL ;
Drury, PL ;
Esmatjes, E ;
Hricik, D ;
Parikh, CR ;
Raz, I ;
Vanhille, P ;
Wiegmann, TB ;
Wolfe, BM ;
Locatelli, F ;
Goldhaber, SZ ;
Lewis, EJ .
ANNALS OF INTERNAL MEDICINE, 2003, 138 (07) :542-549
[5]   Nonsteroidal anti-inflammatory drugs and heart failure [J].
Bleumink, GS ;
Feenstra, J ;
Sturkenboom, MCJM ;
Stricker, BHC .
DRUGS, 2003, 63 (06) :525-534
[6]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[7]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[8]   Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy -: A prospective, placebo-controlled trial [J].
Cice, G ;
Ferrara, L ;
D'Andrea, A ;
D'Isa, S ;
Di Benedetto, A ;
Cittadini, A ;
Russo, PE ;
Golino, P ;
Calabrò, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (09) :1438-1444
[9]   Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey [J].
Cleland, JGF ;
Cohen-Solal, A ;
Aguilar, JC ;
Dietz, R ;
Eastaugh, J ;
Follath, F ;
Freemantle, N ;
Gavazzi, A ;
van Gilst, WH ;
Hobbs, FDR ;
Korewicki, J ;
Madeira, HC ;
Preda, I ;
Swedberg, K ;
Widimsky, J .
LANCET, 2002, 360 (9346) :1631-1639
[10]  
Collins AJ, 2003, NEPHROL DIAL TRANSPL, V18, P2, DOI 10.1093/ndt/gfg1058